Hidden Heart Risk, Explained

Think your standard cholesterol panel tells the whole story? Not quite. In this episode of The Health Pulse, we uncover lipoprotein(a)—or Lp(a)—a genetic marker that quietly drives heart attacks, strokes, and even calcific aortic valve disease. One in five people carry elevated Lp(a), yet it’s rarely tested and barely budges with diet, exercise, or statins.

We explain how Lp(a) acts like LDL with an added twist: the apolipoprotein(a) component makes it more inflammatory, more thrombogenic, and more likely to fuel plaque formation. This triple threat can double or triple cardiovascular risk—even in people whose LDL looks “perfect.”

You’ll learn who should test (especially if you have a family history of early heart disease), how to interpret results in mg/dL or nmol/L, and which companion tests (apoB, hs-CRP, coronary calcium scoring) add crucial context. We also explore treatment: from modest Lp(a) lowering with PCSK9 inhibitors and invasive apheresis to the revolutionary new antisense and siRNA therapies like pelacarsen and olpasiran, which show up to 80–90% reductions in trials.

Until those drugs hit clinics, the prevention strategy is clear: know your Lp(a), lower your LDL and ApoB aggressively, reduce inflammation, and manage every other modifiable risk factor with precision.

If cardiovascular risk is written in your genes, knowledge is your leverage. This episode equips you with the tools to act now—and prepare for the therapies redefining prevention in the near future.

📞 Need lab work done from the comfort of home? QLM offers fast, reliable mobile phlebotomy services—no clinic visit required.

📅 Book your appointment or learn more at:
👉 Quick Lab Mobile
📧 Contact us: [e-mail]

💬 Enjoyed the episode? Leave us a review and let us know what topics you'd like us to cover next! Your feedback helps us bring you the content that matters most.

Disclaimer: The information provided in this podcast is for informational purposes only and should not be considered medical advice. The content discussed is based on research, expert insights, and reputable sources, but it does not replace professional medical consultation, diagnosis, or treatment. We strive to present accurate and up-to-date information, medical research is constantly evolving. Listeners should always verify details with trusted health organizations, before making any health-related decisions. If you are experiencing a medical emergency, such as severe pain, difficulty breathing, or other urgent symptoms, call your local emergency services immediately. By listening to this podcast, you acknowledge that The Health Pulse and its creators are not responsible for any actions taken based on the content of this episode. Your health and well-being should always be guided by the advice of qualified medical professionals.

Episode Transcript

Speaker 00 (00:00):
Welcome to the Health Pulse, your go-to source
for quick, actionable insightson health, wellness, and
diagnostics.
Whether you're looking tooptimize your well-being or stay
informed about the latestin-medical testing, we've got
you covered.
Join us as we break down keyhealth topics in just minutes.
Let's dive in.

Speaker 01 (00:26):
Welcome to the deep dive.
Today we're tackling somethingreally important, but often
overlooked in heart health.
It's called lipoprotein.
LP.
Or you'll often just hear itcalled LPA.
And here's the kicker, thething that really grabs you.
You could be doing, well,everything by the book, your
normal cholesterol check.
LDL, HDL could look absolutelyperfect.
Pristine, even, but, and thisis a big but.

(00:49):
You might still have asignificantly higher risk, maybe
two, maybe three times higherfor a heart attack or stroke.
And the reason, it often comesdown to this one hidden factor,
this LPA.
So our mission today is toreally dive deep into this
hidden risk.
What makes it different is thatit's uh almost entirely
genetic, not really about yourdiet or how much you exercise.

Speaker 02 (01:07):
Aaron Powell That's exactly right.
And we need to be clear, thisisn't some minor detail.
LPA is, well, it's recognizednow as a strong independent risk
factor for atherosclerosis,that's plaque buildup, and also
for those sudden events likeheart attacks and strokes.
The real issue is that standardtests just don't measure it.
So you have many, many peoplewalking around completely
unaware they have this elevatedrisk.

(01:28):
Often they don't find outuntil, unfortunately, something
actually happens.
So awareness, just knowingabout it, is really the first
step.

Speaker 01 (01:34):
Aaron Powell Okay, let's try and unpack this
particle then.
You mentioned it's likecholesterol.
Structurally, it looks a lotlike LDL, right?
The quote unquote badcholesterol.
So what makes LPA so much more,well, dangerous?

Speaker 02 (01:47):
Aaron Powell Yeah, it starts with that LDL-like
core, but the crucial differenceis this extra protein it
carries, something calledapolipoprotein.
It's sort of hitched onto theLDL particle.
And that attachment, that's thekey.
You can think of it like LDL,sure, but maybe LDL carrying, I
don't know, a hidden weapon thatcauses trouble in your
arteries.
And the scale of this, it's whywe need to talk about it.

(02:10):
Around one in five peopleglobally have elevated LPA.
That's 20% of everyone,carrying a common but uh very
underdiagnosed risk factor forheart disease, often happening
much earlier in life.

Speaker 01 (02:21):
One in five.

Speaker 02 (02:22):
Yeah.

Speaker 01 (02:22):
Wow, that's huge.
And this is maybe the mostimportant thing for you, the
listener, to grasp.
Your LPA level is largelyfixed.
It's set by a specific gene,the LPA gene that you inherit.
So, unlike your regularcholesterol, this number doesn't
really change much throughoutyour life.
It means basically one singleblood test can give you a pretty
clear picture of your lifelongrisk profile from the specific
factor.

Speaker 02 (02:42):
Aaron Powell Exactly.
That genetic stability is whygetting tested at least once is
so important, especially ifthere's any family history of
early heart issues.
Now, about that hidden weaponpart, why is LPA seen as such a
problem?
It seems to cause damagethrough multiple ways, not just
one like standard LDL, a kind oftriple threat.

Speaker 01 (03:01):
Aaron Powell Okay, so mechanism number one is

pretty straightforward (03:03):
plaque formation.
Just like its cousin LDL, theLPA particle delivers
cholesterol into your arterywalls.
That directly helps build upatherosclerotic plaque.
That's the basic cholesteroldeposit function.

Speaker 02 (03:14):
Okay, so it drops off cholesterol, fuels plaque.
Got it, like NDL.
But you said triple threat.
What else is going on?
Where does that extra protein,the epilipoprotein, come into
play?
Right.
So that attached apolipoproteinis where the second mechanism
kicks in, thrombosis orclotting.
This protein actually looks abit like another protein
involved in breaking down bloodclots, plasminogen.
It gets in the way, it sort ofjams the system your body uses

(03:37):
to dissolve clots.
So it creates what we call apro-thrombotic environment.
Meaning if a plaque does breakopen, you're much more likely to
form a dangerous clot rightthen and there.
And that sudden clot is whatcauses a heart attack or a
stroke.

Speaker 01 (03:50):
Aaron Powell Hold on, so it's not just building
the plaque, it's activelystopping your body from cleaning
up potential blockagesafterwards.
That sounds really insidious.

Speaker 02 (04:00):
The third element is inflammation.
LPA particles tend to carrythese things called oxidized
phospholipids.
Think of them as inflammatorysignals.
When LPA gets into the arterywall, it brings these signals
with it, triggering localizedinflammation.
And inflammation makes thoseplaques angrier, less stable,
and much more prone to rupturingunexpectedly.

Speaker 01 (04:19):
So building plaque, increasing clot risk, and
fanning the flames ofinflammation.
Wow.
Looking at the research, thistriple threat really translates
into a massive risk increase,doesn't it?
We're seeing figures like uhtwo to three times greater risk
of premature heart disease forpeople with high LPA.
And crucially, that's even ifall their other standard
numbers, like LDL, lookperfectly fine, that really

(04:42):
highlights why just checkingstandard lipids isn't enough.

Speaker 02 (04:45):
Absolutely.
And the impact isn't justlimited to the coronary arteries
either.
We now have strong evidencelinking high LPA to another
serious condition, calcificaortic valve stenosis.
That's where the main valveleading out of your heart gets
stiff and narrowed.
So it seems LPA contributes toproblems in heart valves too,
not just arteries, it's asystemic issue.

Speaker 01 (05:05):
Okay, this brings us to a really practical point:
detection.
You'd think something thiscommon and this dangerous would
be part of every checkup.
But the challenge, as youmentioned, is that high LPA
doesn't cause any symptoms youcan feel.
Nothing.
And you can't really diet orexercise it away significantly,
so you have to actively look forit.

Speaker 02 (05:22):
Precisely.
We often rely on clues,indirect signs.
The biggest red flag thatshould definitely trigger an LPA
test is a strong family historyof cardiovascular disease
happening early.
You know, a parent, sibling,grandparent having a heart
attack or stroke before, say,age 55 in men, or maybe 65 in
women, that's a major signal.

(05:43):
We also know there are geneticvariations, and certain ethnic
groups, including people ofAfrican ancestry, tend to have
higher LPA levels more often.
That's another factor toconsider.

Speaker 01 (05:53):
So if it's not on the standard panel and there are
no release symptoms, how dopeople usually find out they
have high LPA right now?

Speaker 02 (06:01):
Well, sometimes it's picked up if a doctor orders a
more advanced lipid panel, buthonestly, that's less common.
More often it's discoveredbecause of clinical suspicion.
You know, a doctor seessomeone, maybe relatively young,
who's had a heart attack orstroke, they look at the
person's chart, see normal LDLand normal triglycerides, and
think, wait a minute, thisdoesn't add up.
That mismatch serious heartdisease, despite seemingly good
standard cholesterol numbers,that's a huge prompt to

(06:24):
specifically test for LPA.

Speaker 01 (06:26):
It seems like a catch-22.
You often don't test for ituntil after the event you were
trying to prevent.
If 20% of us have this and therisk is fixed and significant,
why isn't it just routine, likechecking blood pressure?

Speaker 02 (06:38):
Ah, and that leads us straight into the biggest
historical challenge, treatment.
Or rather, the lack ofeffective treatment for decades.
LPA just doesn't respond wellto our usual go-to strategies.
Take statins, for example, themost common cholesterol drugs,
they generally have little to noeffect on LPA levels.
In fact, in some people, theymight even cause a small
increase.
And as we've said, lifestylechanges, diet, exercise, while

(07:00):
fantastic for overall health,they just don't significantly
lower this genetically drivennumber.
So for a long time, doctorsthought, well, even if I find
it, what can I really do aboutit?
The options were and still aresomewhat limited.
We have PCSK9 inhibitors.
These are powerful injectabledrugs, mainly used for very high
LDL.
They do lower LPA, but onlymodestly, maybe around 20%,
perhaps 30% reduction.

(07:20):
Good, but not dramatic for LPA.
And then for the absolutehighest risk patients, there's
something called lepoproteinapharesis.
It's basically like dialysis,but it filters lipids, including
LPA, out of your blood.
Highly effective, but also veryinvasive, time-consuming, and
expensive, reserved for extremecases.

unknown (07:38):
Aaron Powell Right.

Speaker 01 (07:38):
So it sounds like we've mostly been managing
around the edges, trying tocontrol all the other risk
factors even more aggressivelyif LPA is high.
Because we couldn't directlytackle the LPA itself.
But this is where things getreally exciting, isn't it?
Science often has these momentswhere the game suddenly
changes.
What's happening now withtargeted therapies?

Speaker 02 (07:56):
Aaron Ross Powell This really is the breakthrough
era for LPA.
We finally have tools that candirectly target the root cause,
the production of LPA, dictatedby that LPA gene.
We're seeing incredible resultscoming out of late-stage
clinical trials for brand newtypes of drugs.
These are genetic silencingtherapies, things like antisense
oligonucleotides or ASOs.

(08:16):
There's one called pelicarsin,and also SIRINA drugs like
alpacarin and SLN360.
These basically tell the liverto stop making so much LPA.

Speaker 01 (08:25):
Genetic silencing.
That sounds pretty advanced.
And what kind of results arethey seeing?
You mentioned TCSK9 inhibitorsgive maybe a 20-30% reduction.
How do these new drugs compare?

Speaker 02 (08:35):
It's a completely different league.
We're talking about potentiallyhuge reductions.
The early and ongoing studiesare showing these therapies can
lower LPA levels by 80 to 90percent, sometimes even more.
That's what is potentiallytransformative.
If these trials continue toshow benefit and safety, the
expectation is that these drugscould become available in the
next few years.
It would fundamentally changehow we manage this high-risk

(08:57):
condition.

Speaker 01 (08:58):
Wow.
80 to 90 percent.
It's a genuine game changer onthe horizon.

Speaker 00 (09:02):
Yeah.

Speaker 01 (09:02):
Okay, so that's the future, and it looks incredibly
promising.
But let's bring it back toright now.
For you listening, while wewait for these amazing new
treatments, what can youactually do?
What are the proactive steps?

Speaker 02 (09:13):
Okay.
The absolute first thing, andlet's be crystal clear.
LPA is not typically includedin a standard cholesterol test
or lipid panel.
You almost always have to askfor it specifically.
So talk to your doctor.
If you have concerns,especially that family history,
ask for the LPA blood test byname.
When you get the result, it'lllikely be reported in either
milligrams per deciliter MGDL ornanomoles per liter NGL.

(09:37):
The key threshold to be awareof is generally around 50
milligdl.
Or if it's an N mole, that'sroughly 125 nelomoles.
Levels above that mark aretypically considered elevated
risk.

Speaker 01 (09:47):
So 50 milligdl is the number to watch.
Is that the only thing?
Or are there other tests thathelp paint a fuller picture,
especially if that LPA numbercomes back high?

Speaker 02 (09:54):
That's a great question.
Yes, usually we look at it incontext.
Two other tests are often veryhelpful.
First, measuring apolipoproteinB, APOB.
APOB gives you the total countof all the potentially
plaque-causing particles,including LDL and LPA.
If your LPA is high, yourdoctor might set a much lower,
more aggressive target for yourAPOB level.

(10:15):
Second, checking inflammatorymarkers like high sensitivity C
reactive protein, HSCRP.
This tells you if there'sunderlying inflammation in your
body, which could make the highLPA even more dangerous.
And sometimes, particularly ifthe risk seems high based on LPA
and other factors, imaging canbe useful.
A coronary artery calciumscore, or CAC score, is a CT
scan that looks for existinghardened plaque in your heart

(10:37):
arteries.
Finding calcium even a littlebit when you also have high LPA
really signals a need for veryaggressive management of
everything else.

Speaker 01 (10:44):
Okay, putting it all together for right now, while
we wait for those 80-90%reduction therapies, the
strategy is clear.
Step one is early detection.
Find out your LPA number.
And if it is high, then steptwo is relentless aggressive
control of every othermodifiable risk factor.
That means getting your LDLcholesterol, or APOB, way down,

(11:05):
keeping blood pressure perfectlycontrolled, managing
inflammation, not smoking,basically compensating for the
fixed risk of LPA, butoptimizing everything else you
can control.

Speaker 02 (11:14):
That sums it up perfectly.
LPA is this potent geneticallydetermined risk factor that's
been hiding in plain sight fortoo long.
Identifying your level empowersyou and your doctor to
personalize your preventionstrategy, control what's
controllable today, and be readyfor the targeted therapies that
are just around the corner.

Speaker 01 (11:30):
Absolutely.
Knowing your LPA number reallyis power, especially since it's
usually a one-time test thattells you about a stable
lifelong risk.
If you have that family historyor just want to know your full
picture, it's definitely aconversation worth having with
your clinician.
And maybe we could leave youwith this final thought to chew
on.
We've talked about LPA beinglargely genetic, something diet

(11:51):
and exercise don't substantiallychange.
If one in five people carrythis fixed risk, does knowing
this shift how we think abouthealth, risk, and maybe even
accountability?
And how long will it berealistically until checking LPA
stops being something you haveto specifically ask for and
becomes as standard as routineas getting your blood pressure
checked?
Something to consider.

(12:12):
Thanks for joining us for thisdeep dive.

Speaker 00 (12:14):
See you next time.quicklabmobile.com.

(12:34):
Stay informed, stay healthy,and we'll catch you in the next
episode.